Clinical Trial: Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People Living With HIV Receiving Antiretroviral Therapy

U.S., Feb. 12 -- ClinicalTrials.gov registry received information related to the study (NCT06819176) titled 'Lenacapavir Intensification to Disrupt HIV Reservoirs in Virologically Suppressed People Living With HIV Receiving Antiretroviral Therapy' on Feb. 08.

Brief Summary: Pending

Study Start Date: Feb. 16

Study Type: INTERVENTIONAL

Condition: Human Immunodeficiency Virus

Intervention: DRUG: Lenacapavir

Lenacapavir (Sunlenca) is a prescription drug approved by the Food and Drug Administration (FDA) for the treatment of people living with multidrug-resistant HIV. Lenacapavir is always used as part of a combination ART regimen. Participants will receive lenacapavir at 927 mg by subcutaneous injection (2x1.5 mL injections) on day 0 an...